A further study demonstrated the safety and efficacy of Targovax TG01 (a KRAS-targeted vaccine)/GM-CSF in combination with gemcitabine in a phase 1/2 trial (NCT02261714) in resected stage I or II PDA patients [35]. This evidence concerns the gene CSF2 and Patent ductus arteriosus.